News
Start-up secures US$26m to develop technology to reduce preterm births
Novocuff has developed a medical device aimed at extending pregnancy and reducing preterm births
The US medical device company Novocuff has raised US$26m in funding to advance its technology aimed at reducing preterm births.
Preterm premature rupture of membranes and cervical shortening are leading causes of preterm birth, affecting millions of families worldwide each year.
Novocuff aims to address these conditions and improve pregnancy outcomes through what it describes as a “novel” approach.
The company has developed a medical device aimed at stabilising and closing the cervix to retain amniotic fluid and sustain cervical length, with the goal of extending pregnancy.
Series A proceeds are hoped to support Novocuff’s growth plans, including the expansion of its team, execution of a US clinical study, marketing authorisation and early-stage commercialisation.
Amelia Degenkolb, co-founder and CEO of Novocuff, said: “We are thrilled to have the support of a strong and mission-aligned group of investors as we enter this exciting next phase of clinical development.
“This funding catalyses our ability to deliver a solution to a healthcare need for women, and their families and healthcare providers.”
AXA IM Alts, through its Global Healthcare Private Equity Strategy, led the round with a US$14m investment, alongside participation from Laerdal Million Lives Fund, and support from existing investors and new investors Laborie, RH Capital, Avestria Ventures and March of Dimes.
Curt LaBelle, head of healthcare private equity at AXA IM Alts, said: “As the leading cause of infant mortality globally, preterm birth is a serious unaddressed global health issue. The near and long-term negative impacts on the patient, and the economic burden on health systems, have created a pressing and dire situation.
“Given the lack of solutions currently available to address this significant global health challenge, we are thrilled to directly contribute to Novocuff’s mission to improve pregnancy outcomes.
“We have followed Novocuff since its founding and are excited about the company’s progress and clinical data generated to date.
“Our investment should enable completion of a US pivotal trial and the introduction of the Novocuff device to global markets, including low- and middle-income countries.”
He added: “This aligns with our commitment at AXA IM Alts of generating measurable and positive healthcare outcomes alongside attractive long-term financial returns for our investors.”
Becca Shmukler, principal at the Laerdal Million Lives Fund, commented: “Tragically, preterm birth is the number one cause of infant mortality globally.
“When we first met co-founders Amy and Donald and initially invested in the company, we were impressed by their novel technology, expertise, and commitment to addressing this sorely underserved market.
Working with them across the last year has only grown our conviction in Novocuff’s potential to lower the mortality burden associated with preterm birth – perfectly aligned with the Laerdal Million Lives Fund’s life-saving mission.
“With this Series A financing, we are now looking forward to partnering with mission-aligned investors like AXA IM Alts to continue to work toward this goal.”
Eric Schaefer, senior director of portfolio strategy and mission investment at March of Dimes, shared: “Too many babies are born too soon, which is why preventing preterm birth and potentially poor outcomes for mum and baby is critical to March of Dimes.
“The investments we make through our Innovation Fund help to support the development of new solutions such as Novocuff’s device, which we hope will help address pregnancy complications that can lead to preterm birth. We are encouraged by Novocuff’s progress to date and look forward to the results from their upcoming clinical trial.”
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







2 Comments